BGLC logo

BIONEXUS GENE LAB CORP

BGLCNASDAQ
πŸ† #3792 by market capUS Equity
$1.32β–Ό $0.19 (βˆ’14.29%)
Live
1hβ€”
24hβ–Ό 14.3%
7dβ–² 0.0%
14dβ–Ό 14.3%
30dβ–Ό 33.0%
1yβ–Ό 76.0%
🏦Market Cap
$3M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-67.1%
Declining
πŸ“ŠGross Margin
12.2%
Thin
πŸ’΅FCF Margin
31.5%
Strong
βš–οΈP/S Ratio
1.2x
Cheap
Otter Score
51
Weak

Trading Snapshot

Day Range
$1.31 – $1.34
52-Week Range
$1.07 – $6.10
Volume
$1.65B
Avg Volume
$2.01B
Shares Outstanding
2.4M
Next Earnings
Oct 5, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$786,439
P/E Ratio
β€”
P/S Ratio
1.2x
EPS (TTM)
$-1.47
Dividend Yield
β€”

Why Investors Own BGLC

  • βœ“High-growth profile β€” revenue up +20.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 27% gross margin and 9% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$3Mβ–² +23.5% YoY
Gross Margin (TTM)
26.8%β–² +3.4% YoY
Operating Income (TTM)
$695,511β–² +23.5% YoY
Free Cash Flow (TTM)
$283,695β–² +23.5% YoY

About BIONEXUS GENE LAB CORP

A company profile for BIONEXUS GENE LAB CORP isn’t available yet β€” check back soon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
51/100

Analyst Price Target

β“˜
Average Target
$1.73
β–² +30.8% Upside
High Target$2.07
Low Target$1.43
Based on 40 analysts

Latest News & Updates